Sanofi (NASDAQ:SNY) Sets New 1-Year Low - Should You Sell?

Key Points

• Sanofi hit a new 52-week low, trading as low as $43.15 (last $43.35) and currently sits below its 50‑ and 200‑day moving averages of $46.39 and $47.89.
• Several brokerages have trimmed ratings recently, and MarketBeat shows a consensus rating of "Hold" with a $51.00 consensus price target.
• Sanofi raised its annual dividend to $2.4225 (ex‑dividend May 4, payable June 3), with a reported payout ratio of 44.69%.

Sanofi (NASDAQ:SNY - Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $43.15 and last traded at $43.35, with a volume of 2895548 shares changing hands. The stock had previously closed at $46.08.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SNY. Weiss Ratings cut shares of Sanofi from a "hold (c-)" rating to a "sell (d+)" rating in a report on Wednesday, April 29th. Bank of America cut shares of Sanofi from a "buy" rating to a "neutral" rating in a report on Thursday, February 12th. Barclays cut shares of Sanofi from an "overweight" rating to an "equal weight" rating in a report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of Sanofi in a report on Friday, January 16th. Finally, BNP Paribas Exane cut shares of Sanofi from an "outperform" rating to a "neutral" rating and set a $50.00 price objective for the company. in a report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $51.00.

Sanofi Price Performance

The company has a market cap of $105.73 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 1.14 and a beta of 0.35. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company's fifty day moving average price is $46.39 and its two-hundred day moving average price is $47.89.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be issued a $2.4225 dividend. This represents a dividend yield of 559.0%. This is a boost from Sanofi's previous annual dividend of $2.04. The ex-dividend date is Monday, May 4th. Sanofi's dividend payout ratio is currently 44.69%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. AMG National Trust Bank acquired a new position in shares of Sanofi in the first quarter valued at approximately $2,719,000. Bleakley Financial Group LLC boosted its holdings in shares of Sanofi by 21.4% in the first quarter. Bleakley Financial Group LLC now owns 157,264 shares of the company's stock valued at $7,577,000 after buying an additional 27,674 shares during the period. Parr Mcknight Wealth Management Group LLC boosted its holdings in shares of Sanofi by 7.9% in the first quarter. Parr Mcknight Wealth Management Group LLC now owns 33,497 shares of the company's stock valued at $1,614,000 after buying an additional 2,445 shares during the period. Diversify Wealth Management LLC acquired a new position in shares of Sanofi in the first quarter valued at approximately $329,000. Finally, Fifth Third Bancorp boosted its holdings in shares of Sanofi by 1.9% in the first quarter. Fifth Third Bancorp now owns 22,916 shares of the company's stock valued at $1,104,000 after buying an additional 432 shares during the period. Institutional investors and hedge funds own 14.03% of the company's stock.

Sanofi Company Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.